SLC12A3 and breast cancer: In ER–stratified breast cancer analyses, there was weak evidence that NCC inhibition was associated with an increased risk of ER− breast cancer (OR equivalent to 1 mm Hg lower SBP: 1.20, 95% CI 1.02 to 1.40; P = 0.03).